Is early loss of minimal luminal diameter after successful PTCA prevented by c7E3 IIb/IIIa antiplatelet antibody?

被引：0
|
作者：
Leon, MN [1 ]
Gold, HK [1 ]
Mahdi, NA [1 ]
Harrell, L [1 ]
Rodriguez, A [1 ]
Palacios, IF [1 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 1998年 / 31卷 / 02期
关键词：
D O I：
10.1016/S0735-1097(97)83945-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：55A / 55A
页数：1
相关论文
共 49 条
  • [21] Immunolocalization of blocked and unblocked GP IIb-IIIa complexes in platelets during antithrombotic therapy with c7E3 Fab (ReoPro, abciximab)
    Nurden, A
    Poujol, C
    DurrieuJais, C
    Besse, P
    Jordan, R
    Wagner, C
    Nurden, P
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 184 - 184
  • [22] STRIKING CLINICAL BENEFIT WITH PLATELET GP IIB/IIIA INHIBITION BY C7E3 AMONG PATIENTS WITH UNSTABLE ANGINA - OUTCOME IN THE EPIC TRIAL
    LINCOFF, AM
    CALIFF, RM
    ANDERSON, K
    WEISMAN, HF
    TOPOL, EJ
    CIRCULATION, 1994, 90 (04) : 21 - 21
  • [23] Concept and clinical application of platelet glycoprotein IIb/IIIa inhibition with abciximab (c7E3 fab; ReoPro) for the prevention of acute ischemic syndromes
    Anderson, HV
    Jordan, RE
    Weisman, HF
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 1997, 3 (04) : 256 - 266
  • [24] Histopathology of coronary lesions with early loss of minimal luminal diameter after successful percutaneous transluminal coronary angioplasty:: Is thrombus a significant contributor?
    Moreno, PR
    Fallon, JT
    Bernardi, VH
    Harrell, L
    Weissman, NJ
    Fuster, V
    Rodríguez, A
    Palacios, IF
    AMERICAN HEART JOURNAL, 1998, 136 (05) : 804 - 811
  • [25] Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis
    Abulencia, JP
    Tien, N
    McCarty, OJT
    Plymire, D
    Mousa, SA
    Konstantopoulos, K
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (01) : 149 - 156
  • [26] INHIBITION OF PLATELET-AGGREGATION BY ANTIPLATELET GP IIB/IIIA (7E3) FAB MURINE MONOCLONAL-ANTIBODY - RELATIONSHIP TO DOSE
    BHATTACHARYA, S
    MACKIE, I
    MACHIN, S
    LEESE, P
    SCHAIBLE, T
    JORDAN, R
    SMITH, C
    BERGER, H
    LAHIRI, A
    CIRCULATION, 1990, 82 (04) : 602 - 602
  • [27] Direct monitoring of c7E3 and fibrinogen binding to platelets allows differentiation of GP IIb/IIIa blockade and ticlopidine effects on platelet function.
    Bode, C
    Straub, A
    Kohler, B
    Moser, M
    Ruef, J
    Nordt, T
    Peter, K
    CIRCULATION, 1998, 98 (17) : 250 - 250
  • [28] Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab):: Flow and endocytic mechanisms contribute to the transport
    Nurden, P
    Poujol, C
    Durrieu-Jais, C
    Winckler, J
    Combrié, R
    Macchi, L
    Bihour, C
    Wagner, C
    Jordan, R
    Nurden, AT
    BLOOD, 1999, 93 (05) : 1622 - 1633
  • [29] Sudden onset of EDTA-dependent pseudothromboeytopenia after therapy with the glyeoprotein IIb/IIIa antagonist c7E3 Fab (Case report) (vol 79, pg 161, 2000)
    Stiegler, H
    Fischer, Y
    Steiner, S
    Strauer, BE
    Reinauer, H
    ANNALS OF HEMATOLOGY, 2000, 79 (04) : 226 - 226
  • [30] Glycoprotein IIb/IIIa receptor antagonist c7E3 fab and anticoagulants show an additive effect on thrombin-induced platelet aggregation after high coagulant challenge in vitro
    Köstenberger, M
    Gallistl, S
    Cvirn, G
    Roschitz, B
    Muntean, W
    30TH HEMOPHILIA SYMPOSIUM, 2001, : 369 - 377
12345